Newsfeeds Archive - Spark Newswire

1 minute read

Myriad Genetics Study Published In JCO Precision Oncology Shows Co’s Prolaris Test Can Predict Benefit Of Hormone Therapy Treatment In Men With Localized Prostate Cancer

May 16, 4:30 PM

Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN),

MYGN

5 minute read

Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session

By Avi Kapoor

May 8, 1:38 PM

Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday’s session after the company reported first-quarter financial results…

AFIB

3 minute read

Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday

By Avi Kapoor

May 8, 11:11 AM

U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday. Shares of Louisiana-Pacific Corporation…

AMRC

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

May 8, 8:06 AM

Gainers Repare Therapeutics (NASDAQ:RPTX) shares rose 34.1% to $4.4 during Wednesday’s pre-market session. The company’s market cap stands…

CLOV

1 minute read

Myriad Genetics Announces Reorganization Of European Operations And Sale Of EndoPredict Business; No Financial Terms Disclosed, Deal Is Subject To Customary Closing Conditions, Expects The Transaction To Close In Q2 Or Q3 Of 2024.

By Benzinga Newsdesk

May 7, 9:06 AM

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operations to better align company resources to its domestic opportunities

MYGN

4 minute read

Analyst Ratings

Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights

By Benzinga Insights

January 29, 12:01 PM

Across the recent three months, 5 analysts have shared their insights on Myriad Genetics (NASDAQ:MYGN), expressing a variety…

MYGN

1 minute read

Genetic Testing Pioneer Myriad Genetics’ Evolution Draws Analyst Attention Amid New Product(s) Anticipation

By Vandana Singh

December 21, 2:05 PM

Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.

MYGN

3 minute read

Analyst Ratings

Evaluating Myriad Genetics: Insights From 4 Financial Analysts

By Benzinga Insights

December 21, 8:00 AM

During the last three months, 4 analysts shared their evaluations of Myriad Genetics (NASDAQ:MYGN), revealing diverse outlooks from…

MYGN

1 minute read

News

Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient Care

By Benzinga Newsdesk

December 20, 9:03 AM

Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise

MYGN

2 minute read

News

Myriad Genetics Celebrates One Million SneakPeek Results Shared With Expectant Parents

By Benzinga Newsdesk

November 20, 5:19 PM

Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test. Since 2015,

MYGN